Loading
A phase 3 trial in colorectal cancer, run by Peking University Cancer Hospital & Institute, now recruiting.
Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) is a phase 3, randomised interventional study registered as NCT06229041 by Peking University Cancer Hospital & Institute, with a registry enrolment figure of 472 participants, started 2023-03-29 and due to reach its primary completion in 2027-10-01. Interventions recorded: Camrelizumab ＋Immunotherapy. Conditions listed: Rectal Cancer. Primary outcome: The PCR rate between total neoadjuvant treatment ±immunotherapy. Colorectal eligibility wording from the registry: "colorectal adenocarcinoma confirmed by pathology". Sites: China. No results are recorded here; the registry entry is the source.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.